Events occur in chronological order, as detailed below
1. The Lancet published a study by Chinese experts: systematic and comprehensive assessment of the long-term prognosis of patients discharged from the new crown hospital
On January 9, 2021, Beijing time, the international authoritative medical journal "Lancet" published a follow-up study jointly completed by the research group of Professor Cao Bin of the Respiratory Center of China-Japan Friendship Hospital and the research group of Zhang Dingyu and the research group of Wang Jianwei of the Chinese Academy of Medical Sciences for the first time, which systematically and comprehensively assessed the long-term prognosis of 6 months after the onset of the onset of COVID-19 discharge patients; on August 28, Lancet published another study jointly completed by the above research group. The largest longitudinal cohort study of 1-year follow-up of discharged COVID-19 survivors to date.
2. Guidelines for the Diagnosis, Treatment and Prevention of COVID-19 in Adults in China were released
On February 6, 2021, the Chinese Medical Journal released the "Guidelines for the Diagnosis, Treatment and Prevention of COVID-19 In Chinese Adults", which was developed by multidisciplinary experts organized by the Respiratory Disease Branch of the Chinese Medical Association (CTS) and the Respiratory Physicians Branch of the Chinese Medical Doctor Association (CACP), which not only fully complied with the requirements of the international evidence-based medicine writing guidelines, but also the proportion of evidence levels in evidence-based medicine was better than that of similar international guidelines.
3. "The Lancet" published a landmark study by Chinese scholars: 6.9% of the wuhan population was positive for new crown antibodies.
In the early morning of March 19, 2021, Beijing time, the international top medical journal "The Lancet" published a paper by a Chinese scholar entitled "The Persistence of Seroepidemiology and Humoral Immunity of the New Crown: A Follow-up Study Based on the Wuhan Population". This study is a unique seroepidemiological study of single-pass natural infection of COVID-19 in the world, revealing the dynamic changes of serum antibodies after a single-pass COVID-19 infection. The journal commented at the same time that the study was an important milestone in the immunization of patients after the new crown infection.
The study was the first long-term seroepidemiological follow-up survey conducted in Wuhan. After the unsealing of Wuhan in April 2020, representative samples of 9,542 residents from 3,556 households were tested for antibodies to the new coronavirus in all 13 districts under the jurisdiction of Wuhan, using a rigorous multi-stage cluster random sampling method, followed by follow-up in June and October-December. Of the 9542 subjects, 532 tested positive for covid-19 antibodies, and after correction, the population had a positive antibody rate of 6.9%, indicating that even after the outbreak, only a small proportion of the population was infected. 82% of the people who were found to be positive for antibodies did not have any clinical symptoms related to the new crown, and they were asymptomatic infected people, and it was clear that most of the people infected with the new crown virus were asymptomatic infected people.
4. The Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (Revised Edition in 2021) were released
In March 2021, the Chinese Journal of Tuberculosis and Respiratory Disease published the "Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Diseases (Revised Edition 2021)". After 8 years, the Chronic Obstructive Pulmonary Disease Group of the Respiratory Disease Branch of the Chinese Medical Association and the experts of the Chronic Obstructive Pulmonary Disease Working Committee of the Respiratory Physicians Branch of the Chinese Medical Doctor Association have carried out this revision, proposing a strategy that combines risk factors, screening questionnaires and popularization of lung function applications, hoping to improve the early diagnosis rate of COPD and reduce missed diagnoses; comprehensive assessment of diseases, stable drug treatment, assessment of acute exacerbations, standardized treatment, The follow-up visits and the prevention of future acute exacerbations have been adjusted accordingly according to the latest research evidence, and new thinking and prospects have been put forward for the diagnosis and treatment of COPD and the clinical research direction.
5. The Respiratory Physician Branch Committee of the Chinese Medical Doctor Association and other academic associations completed the change
On March 26, 2021, the Fifth Committee of the Respiratory Physician Branch of the Chinese Medical Doctor Association was elected and established in Beijing. The Committee is composed of 133 members from all over the country, and elects the president: Wang Chen, the vice president (in alphabetical order): Wang Wei, Shen Huahao, Chen Rongchang, Chen Liang'an, Lin Jiangtao, Zhao Jianping, Liang Zong'an, Qu Jieming, director general: Dai Huaping and 47 standing committee members.
On December 3, 2021, the second committee of the Respiratory Disease Prevention and Control Professional Committee of the Chinese Preventive Medicine Association was replaced. Professor Yang Ting was elected as the chairman of the committee, and Sun Dejun, Chen Rongchang, Chi Chunhua, Wu Jing, Shan Guangliang, Wu Tangchun, and was elected as the vice chairman of the committee (in alphabetical order of surname).
On December 15, 2021, the second committee of the Respiratory Rehabilitation Professional Committee of the Chinese Rehabilitation Medical Association was replaced. Professor Zhao Hongmei was elected as the chairman of the committee, and Professors Chen Hong, Chen Wenhui, Li Yanming, Liang Zong'an, Song Yuanlin, Xie Lixin, Yang Guoru, Zhao Jianping, Zhang Yunhui and Zhou Yumin were elected as vice chairmen.
6. "Expert Consensus on the Diagnosis and Treatment of Bronchiectasis in Adults in China" was released
In April 2021, the Chinese Journal of Tuberculosis and Respiratory Disease released the "Expert Consensus on the Diagnosis and Treatment of Bronchiectasis in Adults in China", which was led by the Expert Consensus Writing Collaborative Group of Bronchiectasis Experts and the Infectious Disease Group of the Respiratory Disease Branch of the Chinese Medical Association, bringing together the clinical research results and wisdom of many experts in China, referring to the experience of European and American countries, and making a more systematic and comprehensive exposition of the epidemiology, pathogenesis, etiology, clinical diagnosis and identification, treatment, management and patient education of bronchiectasis in China.
7. "Expert Consensus on Topical Application of Adult Anti-Infective Drugs in the Lower Respiratory Tract" was released
In April 2021, the "Expert Consensus on topical application of anti-infective drugs in the lower respiratory tract in adults" was published in the Chinese Journal of Tuberculosis and Respiratory Disease. Led by Professor Qu Jieming, head of the Infectious Disease Group of the Respiratory Disease Branch of the Chinese Medical Association, this consensus proposes the indications, drugs and usage of local anti-infective treatment of adults through the airway on the basis of combing the indications, characteristics, usage and precautions of commonly used local anti-infective drugs of the lower respiratory tract, and provides guidance for standardizing the use of anti-infective drugs through the airway.
8. The "China Smoking Hazards To Health Report 2020" was released, and chinese officials for the first time clarified the hazards of e-cigarettes
On May 28, 2021, the National Health Commission released the "China Smoking Hazards to Health Report 2020", and the chapter on "health hazards of e-cigarettes" that has been hotly discussed in the community and medical circles in recent years has been written into the official report for the first time, which is the first time that Chinese officials have clearly defined that "there is sufficient evidence that e-cigarettes are unsafe and will cause harm to health". The report was led by the National Health Commission, entrusted to the China-Japan Friendship Hospital, with Wang Chen, an academician of the Chinese Academy of Engineering, as the leader of the expert group, and invited authoritative expert groups in the fields of tobacco control, chronic respiratory diseases, malignant tumors, cardiovascular diseases, diabetes, and public health to become expert committees. The report is revised on the basis of the Report on the Health Hazards of Smoking in China (2012 Edition).
9. The list of the first batch of sentinel hospitals of the National Respiratory Medical Quality Control Center was announced
On June 18, 2021, the list of the first batch of sentinel hospitals of the National Respiratory Medical Quality Control Center was announced at the opening ceremony of CACP 2021. The screening of sentinel hospitals is completed by relying on various provincial quality control centers, covering tertiary and secondary comprehensive public hospitals, some comprehensive private hospitals, and taking into account the geographical distribution of sentinel hospitals. At present, 17 provincial quality control centers in Anhui, Hainan, Hubei, Hunan, Jiangxi, Liaoning, Inner Mongolia, Qinghai, Shanxi, Sichuan, Chongqing, Shanghai, Shaanxi, Xinjiang, Shandong, Henan and Tianjin have completed the construction of sentinel hospitals.
10. "Expert Consensus on the Diagnosis and Treatment of Refractory Chronic Cough in China" was released
In August 2021, the "Expert Consensus on the Diagnosis and Treatment of Refractory Chronic Cough in China" was published in the Chinese Journal of Tuberculosis and Respiratory Disease. The consensus was jointly formulated by the Asthma Group of the Respiratory Disease Branch of the Chinese Medical Association and the relevant experts of the Chinese Cough Alliance Organization, and mainly included seven parts: definition, epidemiology, pathogenesis, clinical characteristics, diagnosis, evaluation and treatment, which focused on the diagnosis, evaluation and treatment of refractory chronic cough, aiming to better guide domestic clinical practice and promote related research work.
11. The clinical base of Guangzhou Laboratory and National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University was officially completed
On September 25, the clinical base of The National Respiratory Medicine Center of Guangzhou Laboratory and the First Affiliated Hospital of Guangzhou Medical University was officially completed. The clinical base will do a good job in the whole chain of clinical diagnosis and treatment, scientific research and development, product research and development, achievement transformation, talent training, etc., and gather and attract more high-level projects and talents. The clinical base will also be committed to the construction of respiratory disciplines and related systems, focusing on the construction of respiratory and critical care medicine, thoracic surgery, allergy, and integrated traditional Chinese and Western medicine and other related disciplines, and driving the integration and development of other interdisciplinary disciplines through respiratory radiation.
12. The "Early Screening and Comprehensive Intervention Project for People at High Risk of COPD Disease" was officially launched
On the morning of October 9, 2021, the "National Early Screening and Comprehensive Intervention Project for People at High Risk of Chronic Obstructive Pulmonary Disease" issued and implemented by the National Health Commission was officially launched in Beijing. The Ministry of Finance and the National Health Commission allocated a total of 40 million yuan. This is the first time that the state has invested significant financial support in the field of screening and intervention for chronic respiratory diseases. At present, the project has selected 160 districts and counties in 31 provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps to carry out work, screening and comprehensive intervention for 800,000 people at high risk of COPD.
13. Guidelines for respiratory rehabilitation management of chronic respiratory diseases in China (2021) were released
On October 19, 2021, the "Guidelines for respiratory rehabilitation management of chronic respiratory diseases in China (2021)" were published in the Chinese Journal of Health Management. The guidelines were formulated by experts organized by the Respiratory Physicians Branch of the Chinese Medical Doctor Association, the Respiratory Disease Branch of the Chinese Medical Association, the Respiratory Rehabilitation Professional Committee of the Chinese Rehabilitation Medical Association, and the Editorial Committee of the Chinese Journal of Health Management, based on the current evidence-based medical evidence. The total number of chronic respiratory diseases (CRD) reached 544.9 million, and the number of chronic obstructive pulmonary diseases (referred to as COPD) in China was about 100 million, and CRD became the main burden of disabling and fatal diseases.
14. The results of the two "Chinese Adult Lung Health Research" completed by Chinese scholars were published in internationally renowned journals
On June 26, 2021, Environment International, an authoritative journal in the field of environmental health, published online the research results of "the impact of PM2.5 and its components on the lung health of adults in China cannot be ignored" in the "CPH Study" completed by Chinese scholars. This study confirmed the adverse effects of long-term exposure to PM2.5 and its components on large and small airway function.
On November 23, 2021, the American Journal of Respiratory and Critical Care Medicine, an authoritative journal in the field of respiratory diseases, published another study based on the "Chinese Adult Lung Health Study (CPH) Study", which explored the effects of long-term ozone exposure on lung function and SAD in adults, and is currently the largest study in the world for this study. For the first time, a link between long-term exposure to ozone and SAD disease was established, adding new evidence for early respiratory injury caused by ozone.
15. Zhong Nanshan's respiratory disease prevention and control innovation team won the 2020 National Science and Technology Progress Award Innovation Team Award
The innovation team of Zhong Nanshan respiratory disease prevention and control, with Academician Zhong Nanshan, Professor He Jianxing and Professor Ran Pixin as the academic leaders, won the Innovation Team Award of the 2020 National Science and Technology Progress Award. Since its inception, the team has taken the scientific attitude of seeking truth from facts, daring to speak out and putting life first as the guiding ideology, community prevention and control, early diagnosis and early treatment, and precision treatment as the starting point, and conducted research on the key scientific issues of "epidemiological characteristics, molecular mechanisms and early diagnosis and early intervention of respiratory diseases", and realized the "top of the sky", "standing on the ground" and "for the people" of medical scientific research.
16. The project team led by Li Weimin won the second prize of the National Science and Technology Progress Award in 2020
Professor Li Weimin of the Department of Respiratory and Critical Care Medicine of West China Hospital of Sichuan University led the "Establishment and Clinical Application of Key Technologies for Early And Accurate Diagnosis of Lung Cancer" won the second prize of the National Science and Technology Progress Award in 2020. Since 2001, Professor Li Weimin and his team have long been committed to the basic research and clinical transformation of lung cancer, carried out scientific and technological research, established an early screening and early diagnosis system, broken through the diagnosis and treatment problems, achieved major theoretical innovation and technological breakthroughs, and achieved the goal of "double improvement" of lung cancer early diagnosis rate and 5-year survival rate.
17. The number of participating units in the grass-roots respiratory planning construction project has exceeded 10,000; the standardized construction work of the PCCM section has been carried out for fourteen rounds
On November 12, 2021, the number of participating units in the project "Standardized Diagnosis and Treatment System and Capacity Building for Respiratory Diseases in Primary Medical Institutions" exceeded 10,000, and the number of primary medical institutions declared by the project has reached 10,115.
In 2021, the planning and construction of the PCCM department continued to advance, and a total of 793 secondary and above hospitals were registered, identified and cultivated. In addition, 80 hospitals with a pcCM regulation period of more than 2 years were reviewed this year. Since its launch in May 2018, the project has covered 31 provinces, municipalities and autonomous regions, 314 prefecture-level cities, and 942 county-level cities, and more than 2,800 hospitals have participated in registration, identification and cultivation. A total of 20 provincial, municipal and autonomous region health commissions have issued red-headed documents on capacity building in respiratory disciplines.
18. The first batch of national unified recruitment PCCM trainees completed, and the construction of China's PCCM special training system was initially completed
At the end of 2021, the first PCCM special training national unified completion assessment was held. More than 500 PCCM trainees who entered the training in 2018 participated in the final assessment after strictly reviewing the completion of the training content. This assessment uses the national unified test questions, with reference to the North American PCCM special training test question difficulty standard system, covering the main diseases and technical fields of the PCCM specialty, reflecting the comprehensive and high-level requirements for the clinical ability of PCCM specialists. The holding of this final assessment marks that China's PCCM special training has formed a complete technical and management program from enrollment, training to assessment. China's PCCM training system, which has been built since 2012, has been completed at the beginning.
End of this article
Typography: Jerry
Follow us
![75-year-old PATIENTS with COPD who regularly uses drugs but suddenly suffers from chest pain, and this complication of COPD is fatal![fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)